Resistance to Bevacizumab, a major VEGFA antagonist used in cancer therapy to inhibit angiogenesis, has been shown to be related to Rev-Erbα binding to retinoic acid receptor-related orphan receptor alpha (RORA) responsive element adjacent to circadian clock key regulator BMAL1 E-box in VEGFA proximal promotors, which increases VEGFA mRNA and protein expression [115]. This evidence concerns the gene RORA and cancer.